[12] Patent
[11] Patent No.:GC0010311  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2019                60/2019  
Number of the Decision to Grant the Patent:2019/151113
Date of the Decision to Grant the Patent:25/Apr/2019

[21] Application No.:GC 2016-31978

[22] Filing Date:4/9/2016

[30] Priority:

[33] State [32] Priority date [31] Priority No.
PCT
15/9/2015
PCT/EP2015/071060

[72] Inventors:1- Hamed AISSAOUI،2- Christoph BOSS،3- Patrick BOUIS ،4- Julien HAZEMANN،5- Romain SIEGRIST،6- Markus VON RAUMER

[73] Owner: Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/506; A61P 37/00; C07D 471/04 (2006.01)

[56] Cited Documents:

-WO 2011/117798 A1 (ACTELION PHARMACEUTICALS LTD [CH]; AISSAOUI HAMED [CH]; FRETZ HEINZ [C) 29 September 2011
-WO 2010/054113 A2 (AMIRA PHARMACEUTICALS INC [US]; HUTCHINSON JOHN HOWARD [US]; STEARNS B) 14 May 2010
 
Examiner: PH. Ahlam S. AlMusallam

[54] CRYSTALLINE FORM OF S-2-8-5-CHLOROPYRIMIDIN-2-YLMETHYLAMINO-2-FLUORO-6,7,8,9-TETRAHYDRO-5H-PYRIDO[3,2-B]INDOL-5-YLACETIC ACID
[57] Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
No. of claims: 15     No. of figures: 6


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.